Kidney Cancer

Latest News

Line illustration of a pair of kidneys with a tumor on the left kidney

Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

July 21st 2025

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

By Kyle Doherty

July 21st 2025

Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

By Ashling Wahner

July 18th 2025

Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

By Kyle Doherty

July 1st 2025

AI Tool May Predict Response, Resistance in Advanced RCC

By Kristie L. Kahl
Allie Karas, MA

June 10th 2025

More News

Phase 3 KEYNOTE-564 Meets it Secondary Endpoint in RCC

Chris Ryan

November 5th 2023

Adjuvant pembrolizumab improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence.

SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma

Lindsay Fischer

October 13th 2023

Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.

Lenvatinib/Pembrolizumab Elicits High, Durable Responses in Advanced RCC

Russ Conroy

July 19th 2023

Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.

Subgroup Analysis Shows Pembrolizumab Improves Outcomes in Clear Cell RCC

Russ Conroy

July 18th 2023

Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.

Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective

Lindsay Fischer

January 18th 2023

A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.

<1 2